Sökning: WFRF:(Giugliano M) >
Efficacy and Safety...
-
Charytan, David M.NYU Langone Med Ctr, NY USA; Brigham and Womens Hosp, MA 02115 USA; Harvard Med Sch, MA 02115 USA
(författare)
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
- Artikel/kapitelEngelska2019
Förlag, utgivningsår, omfång ...
-
ELSEVIER SCIENCE INC,2019
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-158544
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-158544URI
-
https://doi.org/10.1016/j.jacc.2019.03.513DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Amgen, Inc.; Janssen Pharmaceuticals; Abbott Laboratories; Clinical Diagnostics; Daiichi-Sankyo; Gilead; GlaxoSmithKline; Roche Diagnostics; Takeda; Novartis; Poxel; Eisai; Genzyme; Pfizer; Amgen; AstraZeneca; National Institute for Health
-
BACK GROUND Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. OBJECTIVES The purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function. METHODS The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) amp;gt;= 70 mg/dl or non-high-density lipoprotein cholesterol amp;gt;= 100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate. RESULTS There were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with amp;gt;= stage 3 CKD. LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively. Relative risk reduction for the primary endpoint was similar for preserved function (hazard ratio [HR]: 0.82; 95% CI: 0.71 to 0.94), stage 2 (HR: 0.85; 95% CI: 0.77 to 0.94), and stage amp;gt;= 3 CKD (HR: 0.89; 95% CI: 0.76 to 1.05); p(int) = 0.77. Relative risk reduction for the secondary endpoint was similar across CKD stages (p(int) = 0.75)-preserved function (HR: 0.75; 95% CI: 0.62 to 0.90), stage 2 (HR: 0.82; 95% CI: 0.72 to 0.93), stage amp;gt;= 3 (HR: 0.79; 95% CI: 0.65 to 0.95). Absolute RRs at 30 months for the secondary endpoint were -2.5% (95% CI: -0.4% to -4.7%) for stage amp;gt;= 3 CKD compared with -1.7% (95% CI: 0.5% to -2.8%) with preserved kidney function. Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage. CONCLUSIONS LDL-C lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. Absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD. (C) 2019 by the American College of Cardiology Foundation.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Sabatine, Marc S.Brigham and Womens Hosp, MA 02115 USA; Harvard Med Sch, MA 02115 USA; Brigham and Womens Hosp, MA 02115 USA
(författare)
-
Pedersen, Terje R.Oslo Univ Hosp, Norway
(författare)
-
Im, KyungAhBrigham and Womens Hosp, MA 02115 USA; Harvard Med Sch, MA 02115 USA; Brigham and Womens Hosp, MA 02115 USA
(författare)
-
Park, Jeong-GunBrigham and Womens Hosp, MA 02115 USA; Harvard Med Sch, MA 02115 USA; Brigham and Womens Hosp, MA 02115 USA
(författare)
-
Pineda, Armando LiraAmgen Inc, CA USA
(författare)
-
Wasserman, Scott M.Amgen Inc, CA USA
(författare)
-
Deedwania, PrakashVet Affairs Cent Calif Healthcare Syst, CA USA
(författare)
-
Olsson, Anders G.Univ Calif San Francisco, CA USA
(författare)
-
Sever, Peter S.Linköpings universitet,Institutionen för hälsa, medicin och vård,Medicinska fakulteten(Swepub:liu)n/a
(författare)
-
Keech, Anthony C.Imperial Coll London, England; Univ Sydney, Australia
(författare)
-
Giugliano, Robert P.Brigham and Womens Hosp, MA 02115 USA; Harvard Med Sch, MA 02115 USA; Brigham and Womens Hosp, MA 02115 USA
(författare)
-
NYU Langone Med Ctr, NY USA; Brigham and Womens Hosp, MA 02115 USA; Harvard Med Sch, MA 02115 USABrigham and Womens Hosp, MA 02115 USA; Harvard Med Sch, MA 02115 USA; Brigham and Womens Hosp, MA 02115 USA
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of the American College of Cardiology: ELSEVIER SCIENCE INC73:23, s. 2961-29700735-10971558-3597
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Charytan, David ...
-
Sabatine, Marc S ...
-
Pedersen, Terje ...
-
Im, KyungAh
-
Park, Jeong-Gun
-
Pineda, Armando ...
-
visa fler...
-
Wasserman, Scott ...
-
Deedwania, Praka ...
-
Olsson, Anders G ...
-
Sever, Peter S.
-
Keech, Anthony C ...
-
Giugliano, Rober ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Journal of the A ...
- Av lärosätet
-
Linköpings universitet